Biohaven (BHVN) Interest Expenses (2021 - 2026)
Biohaven (BHVN) reported Interest Expenses of $10.9 million for Q1 2026, down 92.04% on a YoY basis from $136.8 million in Q1 2025, and down 82.23% sequentially from $61.3 million in Q3 2025.
Biohaven (BHVN) Interest Expenses (2021 - 2026) Analysis & Trends
Biohaven (BHVN) has 6 years of Interest Expenses data on file, last reported at $10.9 million in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses fell 92.04% year-over-year to $10.9 million; the trailing twelve-month figure through Mar 2026 stood at $10.9 million (down 92.04% YoY), and the FY2025 full-year result was $313.4 million, up 3.17% from the prior year.
- Interest Expenses slipped to $10.9 million in Q1 2026, from $61.3 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $509.3 million in Q1 2024 to a low of $86000.0 in Q3 2023.
- A 5-year average of $149.8 million and a median of $61.3 million in 2025 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses plunged 98.64% in 2023 and jumped 496647.67% in 2024, its largest moves.
- Tracing BHVN's Interest Expenses over 5 years: stood at $216.1 million in 2022, then climbed by 20.08% to $259.4 million in 2023, then increased by 17.07% to $303.7 million in 2024, then sank by 79.81% to $61.3 million in 2025, then tumbled by 82.23% to $10.9 million in 2026.
- Business Quant data shows BHVN's Interest Expenses at $10.9 million in Q1 2026, $61.3 million in Q3 2025, and $57.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Biohaven | 2.13 Bn | 1.78 Bn | - | 10.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.90 Mn |
| Mar 31, 2026 | 10.90 Mn |
| Sep 30, 2025 | 61.32 Mn |
| Sep 30, 2025 | 61.32 Mn |
| Jun 30, 2025 | 57.11 Mn |
| Jun 30, 2025 | 57.11 Mn |
| Mar 31, 2025 | 136.82 Mn |
| Mar 31, 2025 | 136.82 Mn |
| Dec 31, 2024 | 303.73 Mn |
| Dec 31, 2024 | 303.73 Mn |
| Sep 30, 2024 | 427.20 Mn |
| Sep 30, 2024 | 427.20 Mn |
| Jun 30, 2024 | 256.02 Mn |
| Jun 30, 2024 | 256.02 Mn |
| Mar 31, 2024 | 509.31 Mn |
| Mar 31, 2024 | 509.31 Mn |
| Dec 31, 2023 | 259.45 Mn |
| Dec 31, 2023 | 259.45 Mn |
| Sep 30, 2023 | 86,000.00 |
| Sep 30, 2023 | 86,000.00 |